NASDAQ · Biotechnology

Adlai Nortye Ltd. (ANL) Stock

$13.26 +2.00% NASDAQ: ANL Healthcare

Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products.

Valuation

MetricValue
Price$13.26
Market Cap$703.84M
P/E Ratio-8.19
P/B Ratio-16.99
P/S Ratio140.77
EPS (TTM)$-3.33
52-Week High$17.25
52-Week Low$0.88
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE591.30%
ROA-49.93%
ROCE229.66%
Gross Margin100.00%
Operating Margin-330.48%
Net Margin-343.86%
Debt/Equity-3.17
Current Ratio0.65

Annual Financials (USD)

Metric20212022202320242025
Revenue$46.0M$0$0$0$5.0M
Operating Profit$-9.0M$-67.0M$-73.0M$-53.0M$-36.0M
Net Profit$-57.0M$-59.0M$-109.0M$-52.0M$-36.0M
EPS$-6.66$-6.93$-15.42$-4.89$-3.33
Op Margin-18.9%———-714.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$132.0M$73.0M$130.0M$71.0M$34.0M
Total Liabilities$317.0M$314.0M$55.0M$46.0M$43.0M
Cash$64.0M$43.0M$91.0M$61.0M$24.0M
Borrowings$13.0M$7.0M$32.0M$27.0M$26.0M

Latest News

Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025 GlobeNewswire · Jul 16, 2026 Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists GlobeNewswire · Jul 13, 2026 Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's What You Should Know Zacks · May 20, 2026 Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year? Zacks · May 14, 2026 Here's Why Adlai Nortye Ltd. Sponsored ADR (ANL) Is a Great 'Buy the Bottom' Stock Now Zacks · May 11, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-3.0M$-43.0M$-57.0M$-52.0M$-34.0M
Investing Cash Flow$-56.0M$27.0M$-11.0M$28.0M$-16.0M
Financing Cash Flow$-1.0M$0$-1.0M$-2.0M$-2.0M
Net Cash Flow$40.0M$-21.0M$49.0M$-31.0M$-37.0M
Free Cash Flow$-4.0M$-44.0M$-57.0M$-52.0M$-34.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.13
EV / EBITDA-43.93
FCF Yield-2.63%
Quick Ratio0.65
Interest Coverage-36.00
Return 1Y755.48%
Return 3Y—
Return 5Y—

Ownership

Insiders Held0.01%
Institutions Held15.96%
Institutions Float Held15.96%
Institutional HolderSharesReport Date
Venrock Adviser, LLC3,212,7312026-03-31
Cormorant Asset Management, LP2,897,8572026-03-31
Squadron Capital Management LLC1,265,2312026-03-31
Balyasny Asset Management LP877,8462026-03-31
Millennium Management Llc681,7752026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADAPAdaptimmune Therapeutics plc $0.05 -3.00% -0.16 $75.16M 0.00%
ADTX $0.01 -77.22% -0.01 $318 0.00%
AIMD $1.49 -3.87% -0.43 $10.97M 0.00%
APLMApollomics, Inc. $18.76 +2.99% -2.41 $20.69M 0.00%
BLRXBioLineRx Ltd. $2.85 -2.45% -1.36 $12.39M 0.00%

About Adlai Nortye Ltd.

Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas. The company's pipeline also features AN0025, a small molecule prostaglandin E receptor 4 antagonist designed to modulate the tumor microenvironment. This candidate is in Phase Ib clinical trials, exploring its efficacy in treating various conditions, including: recurrent non-small cell lung cancer; urothelial cancer (post-anti-PD-1/PD-L1 treatments); recurrent triple-negative breast cancer; microsatellite stable colorectal cancer; and cervical cancer (following standard-of-care treatments). Additionally, ANL is developing AN4005, an oral small-molecule PD-L1 inhibitor. This drug, which is in Phase I clinical trials, aims to induce and stabilize PD-L1 dimerization to disrupt the interaction between PD-1 and PD-L1. Beyond their clinical programs, Adlai Nortye has early-stage research candidates such as AN8025, a multifunctional antibody that acts as a modulator of T cells and antigen-presenting cells, and AN9025, an oral small molecule pan-KRAS inhibitor. Established in 2004, the company's headquarters are situated in Grand Cayman, Cayman Islands.

Adlai Nortye Ltd. is headquartered in US.

Adlai Nortye Ltd. (ANL) stock trades at $13.26 with a market capitalization of $703.84M. The stock is valued at a price-to-earnings (P/E) ratio of -8.19, price-to-book of -16.99, price-to-sales of 140.77. Over the past 52 weeks the stock has ranged between $0.88 and $17.25, and currently trades 23.1% below its 52-week high.

On profitability, Adlai Nortye Ltd. generates a return on equity (ROE) of 591.30% — well above the market average, a sign of a high-quality business, return on capital employed of 229.66%, an operating margin of -330.48%, a net profit margin of -343.86%.

Official website: www.adlainortye.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides